Dr. Andrea Edginton, Hallman Director and Professor at the University of Waterloo School of Pharmacy, has been awarded the prestigious 2026 AFPC–Pfizer Research Career Award from the Association of Faculties of Pharmacy of Canada. The award recognizes research excellence among academic staff who stimulate and foster the development of research programs across all areas of pharmacy.
Dr. Edginton is the third person to hold the Hallman Director position since the School was founded at the University of Waterloo in 2008.
As a professor, Dr. Edginton has authored more than 140 peer-reviewed publications in pharmacokinetic modelling and simulation. Her academic research focuses on the development and application of physiologically based pharmacokinetic (PBPK) and population pharmacokinetic models in pharmaceutical research and human health risk assessment. Her work examines how the physiology of specific populations, particularly underrepresented groups such as neonates, breastfeeding people and patients with rare diseases, affects drug pharmacokinetics, and how this information can be incorporated into mathematical models to optimize drug therapy.
Dr. Edginton also leads the modelling component of the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo) project, which uses advanced pharmacokinetic modelling to tailor prophylactic treatment for people with hemophilia. This free service is used by more than 850 hemophilia treatment centres in over 50 countries, providing clinicians with an easy-to-use tool to optimize medication therapy for their patients.
A successful entrepreneur, educator and researcher, Dr. Edginton is also vice-president of Design2Code Inc., a consulting company that develops and applies scientific models and software to help pharmaceutical companies answer key questions throughout the drug development pipeline. Her primary expertise is in designing pediatric clinical trials through the simulation of virtual children to support dose selection.
In 2022, together with her colleagues Dr. Nardine Nakhla, CEO, and Michael Sevestre, CTO, she co-founded MAPflow Inc., where she serves as COO and president. MAPflow is a novel software-as-a-service platform that supports pharmacists’ clinical decision-making, including minor ailment prescribing.
Dr. Edginton has supervised numerous MSc and PhD trainees and is recognized for fostering highly skilled scientists working at the intersection of pharmacy, engineering and data science. Her contributions to research, training and leadership have earned her multiple national and international awards and positioned her as a key voice in precision therapeutics.
For her work with WAPPS-Hemo, she received the American College of Clinical Pharmacology’s prestigious 2022 Roger Jelliffe Individualized Therapy Award. She was also a 2024 recipient of the WXN Canada’s Most Powerful Women: Top 100 (Executive Leaders) Award and has been recognized four times in the past 10 years with the University of Waterloo’s Outstanding Performance Award.
Beyond the University, Dr. Edginton is co-chair of the International Hemophilia Prophylaxis Study Group – Clinical Pharmacology, a past chair of the AFPC Council of Deans representing Canada’s PharmD programs, and a board member of the Ontario College of Pharmacists, the regulatory body for pharmacy professionals in Ontario.
Congratulations Dr. Edginton!